PharmaTimes https://pharmatimes.com in-depth news, features and insights for the pharmaceutical and healthcare sectors Thu, 11 Jun 2026 09:31:45 +0000 en-US hourly 1 https://pharmatimes.com/wp-content/uploads/2023/11/PT-icon-150x150.png PharmaTimes https://pharmatimes.com 32 32 232894315 NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma https://pharmatimes.com/news/nice-backs-daratumumab-quadruplet-for-newly-diagnosed-transplant-ineligible-myeloma/ Thu, 11 Jun 2026 09:31:45 +0000 https://pharmatimes.com/?p=104720 Final draft guidance recommends D‑VRd on the NHS in England and Wales

]]> 104720 Anocca doses first patients with precision TCR‑T therapy https://pharmatimes.com/news/anocca-doses-first-patients-with-precision-tcr-t-therapy/ Thu, 11 Jun 2026 09:21:53 +0000 https://pharmatimes.com/?p=104718 Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial

]]> 104718 Connecta launches phase 2a trial of neuroplasticity modulator https://pharmatimes.com/news/connecta-launches-phase-2a-trial-of-neuroplasticity-modulator/ Wed, 10 Jun 2026 13:41:32 +0000 https://pharmatimes.com/?p=104716 Study marks major milestone for CTH120 as company advances disease‑modifying ambitions

]]> 104716 Aquipta recommended by NICE for acute migraine treatment https://pharmatimes.com/news/aquipta-recommended-by-nice-for-acute-migraine-treatment/ Wed, 10 Jun 2026 13:35:05 +0000 https://pharmatimes.com/?p=104714 Guidance paves the way for NHS access for eligible adults in England and Wales

]]> 104714 Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma https://pharmatimes.com/news/talvey-accepted-for-use-in-scotland-for-relapsed-and-refractory-multiple-myeloma/ Tue, 09 Jun 2026 13:58:01 +0000 https://pharmatimes.com/?p=104691 SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

]]> 104691 Alzecure enters collaboration and with Lilly for Alzheimer’s project https://pharmatimes.com/news/alzecure-enters-collaboration-and-with-lilly-for-alzheimers-project/ Tue, 09 Jun 2026 13:55:17 +0000 https://pharmatimes.com/?p=104689 Partnership grants Lilly global rights to Alzstatin ACD680

]]> 104689 Survodutide trial data show targeted visceral and liver fat reductions https://pharmatimes.com/news/survodutide-trial-data-show-targeted-visceral-and-liver-fat-reductions/ Mon, 08 Jun 2026 08:24:48 +0000 https://pharmatimes.com/?p=104679 Phase 3 results highlight metabolic benefits alongside weight loss

]]> 104679 First patient enrolled in German real‑world study of Pepaxti https://pharmatimes.com/uncategorized/first-patient-enrolled-in-german-real-world-study-of-pepaxti/ Mon, 08 Jun 2026 08:19:29 +0000 https://pharmatimes.com/?p=104677 Treatment set to be used in routine multiple myeloma care

]]> 104677 Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity https://pharmatimes.com/news/johnson-johnson-reports-phase-2-data-showing-nipocalimab-reduced-sle-disease-activity/ Thu, 04 Jun 2026 10:10:38 +0000 https://pharmatimes.com/?p=104672 Late‑breaking EULAR results highlight sustained responses through week 52

]]> 104672 European approval enables measles protection with CSL’s immunoglobulin Privigen https://pharmatimes.com/news/european-approval-enables-measles-protection-with-csls-immunoglobulin-privigen/ Thu, 04 Jun 2026 10:01:44 +0000 https://pharmatimes.com/?p=104670 Commission authorisation expands access to passive measles prophylaxis for vulnerable patients

]]> 104670